CA2231803C - Lipid extract having anti-inflammatory activity - Google Patents
Lipid extract having anti-inflammatory activity Download PDFInfo
- Publication number
- CA2231803C CA2231803C CA002231803A CA2231803A CA2231803C CA 2231803 C CA2231803 C CA 2231803C CA 002231803 A CA002231803 A CA 002231803A CA 2231803 A CA2231803 A CA 2231803A CA 2231803 C CA2231803 C CA 2231803C
- Authority
- CA
- Canada
- Prior art keywords
- lipid extract
- use according
- supercritical fluid
- pco
- fluid extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 150000002632 lipids Chemical class 0.000 title claims abstract description 46
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 28
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 32
- 241001537211 Perna canaliculus Species 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 35
- 235000020638 mussel Nutrition 0.000 claims description 23
- 206010003246 arthritis Diseases 0.000 claims description 22
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- 239000004006 olive oil Substances 0.000 claims description 14
- 235000008390 olive oil Nutrition 0.000 claims description 13
- 229960005233 cineole Drugs 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940087305 limonene Drugs 0.000 claims description 4
- 235000001510 limonene Nutrition 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 239000010776 emu oil Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims description 2
- 125000003555 cineol group Chemical group 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 30
- 230000002456 anti-arthritic effect Effects 0.000 abstract description 8
- 210000002683 foot Anatomy 0.000 description 28
- 241000700159 Rattus Species 0.000 description 24
- 238000003556 assay Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 206010030113 Oedema Diseases 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 9
- 235000010418 carrageenan Nutrition 0.000 description 9
- 229920001525 carrageenan Polymers 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 240000007817 Olea europaea Species 0.000 description 7
- 206010036030 Polyarthritis Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 208000030428 polyarticular arthritis Diseases 0.000 description 7
- 244000189799 Asimina triloba Species 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 230000002917 arthritic effect Effects 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 235000006264 Asimina triloba Nutrition 0.000 description 5
- 235000009467 Carica papaya Nutrition 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940009100 aurothiomalate Drugs 0.000 description 5
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- -1 cachets Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 231100000420 gastrotoxicity Toxicity 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940124347 antiarthritic drug Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000001387 apium graveolens Substances 0.000 description 2
- 230000003286 arthritogenic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010061430 Arthritis allergic Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101100043727 Caenorhabditis elegans syx-2 gene Proteins 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 101100535673 Drosophila melanogaster Syn gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- UGOFYAXVVVXMQT-UHFFFAOYSA-N clobuzarit Chemical compound C1=CC(COC(C)(C)C(O)=O)=CC=C1C1=CC=C(Cl)C=C1 UGOFYAXVVVXMQT-UHFFFAOYSA-N 0.000 description 1
- 229950007550 clobuzarit Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002905 effect on arthritis Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- UGDPYGKWIHHBMB-UHFFFAOYSA-N lobenzarit Chemical compound OC(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C(O)=O UGDPYGKWIHHBMB-UHFFFAOYSA-N 0.000 description 1
- 229950005662 lobenzarit Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
- 229950000752 methylhexaneamine Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN5311/95 | 1995-09-11 | ||
| AUPN5311A AUPN531195A0 (en) | 1995-09-11 | 1995-09-11 | Lipid extract having anti-inflamatory activity |
| PCT/AU1996/000564 WO1997009992A1 (en) | 1995-09-11 | 1996-09-10 | Lipid extract having anti-inflammatory activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2231803A1 CA2231803A1 (en) | 1997-03-20 |
| CA2231803C true CA2231803C (en) | 2004-11-23 |
Family
ID=3789640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002231803A Expired - Lifetime CA2231803C (en) | 1995-09-11 | 1996-09-10 | Lipid extract having anti-inflammatory activity |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6083536A (https=) |
| EP (1) | EP0850068B1 (https=) |
| JP (1) | JP4101876B2 (https=) |
| AT (1) | ATE293984T1 (https=) |
| AU (1) | AUPN531195A0 (https=) |
| CA (1) | CA2231803C (https=) |
| DE (1) | DE69634666T2 (https=) |
| DK (1) | DK0850068T3 (https=) |
| ES (1) | ES2241001T3 (https=) |
| PT (1) | PT850068E (https=) |
| WO (1) | WO1997009992A1 (https=) |
| ZA (1) | ZA967626B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
| US6479277B2 (en) | 1997-06-04 | 2002-11-12 | Cellular Improvements Ltd. | Method and apparatus for disruption of biological material |
| SE9703085D0 (sv) * | 1997-08-27 | 1997-08-27 | Micro Active Protein In Sweden | Anti-microbial composition |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| US7220427B2 (en) | 1998-07-08 | 2007-05-22 | Oryxe | Mixture for transdermal delivery of low and high molecular weight compounds |
| DE19838794A1 (de) * | 1998-08-26 | 2000-03-09 | Aristavet Veterinaerspezialita | Zusammensetzung zur Behandlung von Osteoarthritis und zur nutritiven Behandlung des Gelenkknorpels |
| AUPP910699A0 (en) * | 1999-03-10 | 1999-04-01 | Pharmalink International Limited | Inhibitor of lipoxygenase pathways |
| US6596303B1 (en) * | 1999-03-22 | 2003-07-22 | Mars Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| AU2005200953B2 (en) * | 1999-03-22 | 2007-07-12 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| US20020018787A1 (en) * | 1999-05-21 | 2002-02-14 | Roger V. Kendall | Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| JP2003504408A (ja) * | 1999-07-21 | 2003-02-04 | ボマック・ラボラトリーズ・リミテッド | 炎症及び／又は退行性疾患に対処する組成物 |
| DE60012026T2 (de) * | 1999-08-26 | 2004-12-30 | Ganeden Biotech, Inc., San Diego | Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| AU9347701A (en) * | 2000-09-22 | 2002-04-02 | Pharmalink Internat Ltd | Immunomodulatory preparation |
| US7519546B2 (en) * | 2001-04-30 | 2009-04-14 | General Electric Company | Maintaining synchronization of information published to multiple subscribers |
| CA2493888C (en) | 2001-07-27 | 2013-07-16 | Neptune Technologies & Bioressources Inc. | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
| AUPS082102A0 (en) * | 2002-03-01 | 2002-03-21 | Women's And Children's Hospital | Therapeutic properties of oils |
| WO2003077811A1 (en) * | 2002-03-14 | 2003-09-25 | Mcclung Jackie H | Pharmaceutically active compounds containing phosphorous defficient oil |
| DE20210182U1 (de) * | 2002-07-01 | 2002-10-02 | Bio-Innovation Development Ltd., Christchurch | Wirkstoffzusammensetzung aus Bestandteilen der Grünlippenmuschel (perna canaliculus) und zusätzlichen Omega-3-Fettsäuren |
| EP1603405A4 (en) * | 2003-03-14 | 2006-05-24 | Foodscience Corp | METHOD FOR THE TREATMENT OF CANCER WITH PERNA CANALICULUS INGREDIENTS (EN) AND PERNA CANALICULUS EXTRACTS |
| US7052715B2 (en) * | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| US7572464B2 (en) | 2004-01-30 | 2009-08-11 | Bionovate Limited | Solvent extraction of lipids such as essential fatty acids |
| GB0411165D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Hyaluronic acid containing pharmaceutical or veterinary compounds |
| GB0411166D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
| US20060039992A1 (en) * | 2004-06-02 | 2006-02-23 | Miller Bruce A Jr | Novel compositions and methods utilizing green-lipped mussel and fatty acids |
| WO2006052150A1 (en) * | 2004-11-15 | 2006-05-18 | University Of Otago | Mussel extract composition with enhanced anti-inflammatory activity |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| NZ563125A (en) * | 2005-06-03 | 2009-11-27 | Mcfarlane Marketing Aust Pty L | Lipid extract of mussels and method for preparation thereof |
| NZ547429A (en) * | 2006-05-24 | 2009-09-25 | Ind Res Ltd | Extraction of highly unsaturated lipids with liquid dimethyl ether |
| US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| HUE033687T2 (en) | 2006-07-18 | 2017-12-28 | Techfields Biochem Co Ltd | Ibuprofen positively charged water soluble prodrugs with very fast skin penetration rates |
| PL2046727T3 (pl) | 2006-07-25 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę |
| PL2049482T3 (pl) | 2006-08-08 | 2016-04-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę |
| JP5466006B2 (ja) | 2006-09-03 | 2014-04-09 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ |
| CN101506168B (zh) | 2006-09-03 | 2014-12-10 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药 |
| WO2008035756A1 (en) * | 2006-09-22 | 2008-03-27 | Heimat Co., Ltd. | Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin |
| PL2084124T3 (pl) * | 2006-10-02 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę |
| CN101522692A (zh) | 2006-10-11 | 2009-09-02 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 |
| NZ552238A (en) | 2006-12-20 | 2009-07-31 | Seperex Nutritionals Ltd | An extract |
| US8337916B2 (en) * | 2007-06-01 | 2012-12-25 | Laila Nutraceuticals | Use of Aphanamixis polystacha extracts or fractions against 5-lipoxygenase mediated diseases |
| WO2008149181A1 (en) * | 2007-06-04 | 2008-12-11 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
| US8487007B2 (en) * | 2008-04-28 | 2013-07-16 | Vermont Italia Srl | Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide |
| WO2010065936A1 (en) | 2008-12-04 | 2010-06-10 | Chongxi Yu | High penetration compositions and their applications |
| JP5313064B2 (ja) * | 2009-07-03 | 2013-10-09 | 株式会社ノエビア | 中性脂肪蓄積促進剤、豊胸剤 |
| CN116898848A (zh) | 2012-01-18 | 2023-10-20 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| WO2014106048A2 (en) | 2012-12-31 | 2014-07-03 | Jrx Biotechnology, Inc. | Liquid topical pharmaceutical nano-emulsion formulations |
| JP6176655B2 (ja) * | 2013-07-02 | 2017-08-09 | 御木本製薬株式会社 | マトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤、老化防止用皮膚外用剤、シワ防止用皮膚外用剤、慢性関節リウマチ及び他の疾患の治療又は予防剤 |
| KR102468519B1 (ko) * | 2015-07-20 | 2022-11-21 | 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 | 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용 |
| KR20180053318A (ko) | 2015-09-17 | 2018-05-21 | 제이알엑스 바이오테크놀로지, 인코포레이티드 | 피부 수화 또는 보습을 향상시키기 위한 접근법 |
| US20200016215A1 (en) * | 2016-12-20 | 2020-01-16 | Sanford Limited | Bioactive mussel compositions and/or extracts |
| CN111432654A (zh) * | 2017-12-04 | 2020-07-17 | 雾凇科技有限公司 | 从甲壳类捕获物中生产蛋白质磷脂复合物的方法 |
| US11654163B2 (en) * | 2017-12-22 | 2023-05-23 | Pharmalink International Limited | Lipid combinations |
| US12604918B2 (en) | 2020-01-21 | 2026-04-21 | Lintbells Limited | Synergistic compositions |
| KR20220131272A (ko) | 2020-01-21 | 2022-09-27 | 린트벨스 리미티드 | 상승효과가 있는 조성물 |
| CN113041263B (zh) * | 2021-03-15 | 2023-07-25 | 青岛大学 | 一种贻贝功能性脂质在制备治疗2型糖尿病产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0010061B1 (en) * | 1978-09-25 | 1983-07-13 | Stuart John Mc Farlane | Pharmaceutical preparations containing a mollusc extract |
| US4801453A (en) | 1984-05-01 | 1989-01-31 | James M. Broadbent | Stabilized mussel extract |
| AU3156595A (en) * | 1994-08-11 | 1996-03-07 | J.W. Broadbent Nominees Pty. Ltd. | Anti-inflammatory preparation |
| AUPM740594A0 (en) | 1994-08-11 | 1994-09-01 | J.W. Broadbent Nominees Pty. Ltd. | Anti-inflammatory preparation |
| AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
-
1995
- 1995-09-11 AU AUPN5311A patent/AUPN531195A0/en not_active Abandoned
-
1996
- 1996-09-10 US US09/029,957 patent/US6083536A/en not_active Expired - Lifetime
- 1996-09-10 WO PCT/AU1996/000564 patent/WO1997009992A1/en not_active Ceased
- 1996-09-10 JP JP51149997A patent/JP4101876B2/ja not_active Expired - Lifetime
- 1996-09-10 ZA ZA9607626A patent/ZA967626B/xx unknown
- 1996-09-10 DE DE69634666T patent/DE69634666T2/de not_active Expired - Lifetime
- 1996-09-10 AT AT96929129T patent/ATE293984T1/de active
- 1996-09-10 PT PT96929129T patent/PT850068E/pt unknown
- 1996-09-10 EP EP96929129A patent/EP0850068B1/en not_active Expired - Lifetime
- 1996-09-10 CA CA002231803A patent/CA2231803C/en not_active Expired - Lifetime
- 1996-09-10 DK DK96929129T patent/DK0850068T3/da active
- 1996-09-10 ES ES96929129T patent/ES2241001T3/es not_active Expired - Lifetime
-
2000
- 2000-07-05 US US09/610,484 patent/US6346278B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69634666D1 (de) | 2005-06-02 |
| AUPN531195A0 (en) | 1995-10-05 |
| EP0850068A1 (en) | 1998-07-01 |
| EP0850068A4 (en) | 2000-09-13 |
| JP4101876B2 (ja) | 2008-06-18 |
| DK0850068T3 (da) | 2005-08-15 |
| CA2231803A1 (en) | 1997-03-20 |
| ATE293984T1 (de) | 2005-05-15 |
| JPH11512400A (ja) | 1999-10-26 |
| ZA967626B (en) | 1997-09-03 |
| US6083536A (en) | 2000-07-04 |
| DE69634666T2 (de) | 2006-04-27 |
| EP0850068B1 (en) | 2005-04-27 |
| US6346278B1 (en) | 2002-02-12 |
| ES2241001T3 (es) | 2005-10-16 |
| PT850068E (pt) | 2005-08-31 |
| WO1997009992A1 (en) | 1997-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2231803C (en) | Lipid extract having anti-inflammatory activity | |
| JP6080312B2 (ja) | 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法 | |
| AU702338B2 (en) | Method and compositions for treating impotence | |
| CA1263604A (en) | Pharmaceutical oil-in-water type micro-emulsion | |
| JP5587969B2 (ja) | 炎症及び疼痛の処置用の化合物 | |
| AU2008210557B2 (en) | Hyaluronate compositions | |
| JPS6160620A (ja) | ピログルタミン酸エステル類を含有する医薬品組成物 | |
| CN102510752A (zh) | 含有大环内酯类免疫抑制药物的新颖的药物组合物 | |
| US5166219A (en) | Systemic anti-inflammatory treatment | |
| US5194451A (en) | Systemic anti-inflammatory treatment | |
| CN113274343B (zh) | 多元醇作为助溶剂在秋水仙碱外用组合物中的应用 | |
| TR201909353T4 (tr) | Multipl skleroz tedavisi. | |
| CN105407885A (zh) | 包含ω-3脂肪酸和番茄的番茄红素的组合 | |
| EP2019666B1 (en) | Pharmaceutical preparations for transdermal use | |
| US20080274209A1 (en) | Methods of treating inflammation | |
| CN112040958A (zh) | 含肽调配物 | |
| AU703368B2 (en) | Lipid extract having anti-inflammatory activity | |
| US20230149352A1 (en) | Uses of apremilast | |
| EP0003382B1 (en) | Solvent vehicle for therapeutics and pharmaceutical composition containing it | |
| JP5223307B2 (ja) | 坐剤 | |
| US10517855B1 (en) | Interleukins activity inhibiting composition | |
| RU2493861C1 (ru) | Биологически активный комплекс, обладающий противоаллергическим действием | |
| CN114159435A (zh) | 附子灵在制备治疗关节炎药物中的应用 | |
| JP2021070661A (ja) | Ｔｓｌｐ遺伝子発現抑制用、ｉｌ−３３遺伝子発現抑制用、又はフィラグリン産生促進用組成物 | |
| DE2244558A1 (de) | Arzneimittel mit ulcusheilender wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160912 |